Home
About Us
About Us
Certificate
Workshop
Safety and Environmental Protection
Products
Product Category
Active Pharmaceutical Ingredient (API)
Iguratimod
Apremilast
Bromhexine HCl
Tofacitinib Citrate
Urapidil Hydrochloride
Garlicin
Celecoxib
Dexmedetomidine Hydrochloride
Rocuronium Bromide
Lifitegrast
Difelikefalin
Gemcitabine HCl
Pharmaceutical Intermediate
Gemcitabine HCl T9
Gemcitabine HCl T8
Gemcitabine HCl T6
Gemcitabine HCl T3
Tetrazole
1H-tetrazole
5-amino Tetrazole
Iminazole
4,5-Dicyanoimidazole
Pyridine
2,6-Diaminopyridine
Heterocyclics
4-Nitrobenzoic Acid
News
Blog
Company News
Industry News
R&D
Send Inquiry
Contact Us
English
Untranslated
English
Español
Português
русский
Français
日本語
Deutsch
tiếng Việt
Italiano
Nederlands
ภาษาไทย
Polski
한국어
Svenska
magyar
Malay
বাংলা ভাষার
Dansk
Suomi
हिन्दी
Pilipino
Türkçe
Gaeilge
العربية
Indonesia
Norsk
تمل
český
ελληνικά
український
Javanese
فارسی
தமிழ்
తెలుగు
नेपाली
Burmese
български
ລາວ
Latine
Қазақша
Euskal
Azərbaycan
Slovenský jazyk
Македонски
Lietuvos
Eesti Keel
Română
Slovenski
मराठी
Srpski језик
More Language
Sitemap
Home
About Us
About Us
|
Certificate
|
Workshop
|
Safety and Environmental Protection
Products
Product Category
Active Pharmaceutical Ingredient (API)
Iguratimod
CAS#123663-49-0
|
Arthritis Iguratimod
|
Rheumatic Arthritis Iguratimod
|
CAS NO.123663-49-0
|
CAS 123663-49-0
|
123663-49-0
|
N-(3-Formamido-4-oxo-6-phenoxy-4H-chromen-7-yl)methanesulfonamide N-[7-(Methanesulfonamido)-4-oxo-6-phenoxy-4H-chromen-3-yl]formamide
|
Iguratimod API
Apremilast
CAS#608141-41-9
|
CAS NO. 608141-41-9
|
CAS 608141-41-9
|
608141-41-9
|
Plaque Psoriasis Apremilast
|
(+)-N-[2-[1(S)-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl) ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]acetamide
|
Apremilast API
Bromhexine HCl
CAS#611-75-6
|
2-Amino-3,5-dibromo-N-cyclohexyl-N-methylbenzylamine Hydrochloride
|
N-(2-Amino-3,5-dibromobenzyl)-N-methylcyclohexylamine Hydrochloride
|
CAS NO.611-75-6
|
CAS 611-75-6
|
611-75-6
|
Bromhexine Hydrochloride API
|
Bromhexine HCl API
Tofacitinib Citrate
CAS#540737-29-9
|
(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-b-oxo-1-piperidinepropanenitrile: 2-Hydroxy-1,2,3-propanetricarboxylate
|
CAS NO.540737-29-9
|
CAS 540737-29-9
|
540737-29-9
|
Tofacitinib Citrate API
Urapidil Hydrochloride
CAS#64887-14-5
|
6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione
|
6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl-2,4(1H,3H)-pyrimidinedione Hydrochloride
|
CAS NO.64887-14-5
|
CAS 64887-14-5
|
64887-14-5
|
Urapidil Hydrochloride API
Garlicin
Diallyl Trisulfide
|
CAS#2050-87-5
|
CAS NO.2050-87-5
|
CAS 2050-87-5
|
2050-87-5
|
Garlicin Oil
Celecoxib
CAS#169590-42-5
|
Ostarthritis Celecoxib
|
CAS NO.169590-42-5
|
CAS 169590-42-5
|
169590-42-5
|
Celecoxib API
Dexmedetomidine Hydrochloride
4-[(1r)-1-(2,3-dimethylphenyl)ethyl]-3h-imidazole Hydrochloride
|
4-[(1r)-1-(2,3-dimethylphenyl)ethyl]-3h-imidazole
|
CAS#145108-58-3
|
CAS NO.145108-58-3
|
CAS 145108-58-3
|
145108-58-3
|
Dexmedetomidine HCl API
|
Dexmedetomidine Hydrochloride API
Rocuronium Bromide
CAS#119302-91-9
|
CAS NO.119302-91-9
|
CAS 119302-91-9
|
119302-91-9
|
Rocuronium Bromide API
Lifitegrast
N-[[2-(6-Benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl]carbonyl]-3-(methylsulfonyl)-L-phenylalanine
|
CAS#1025967-78-5
|
CAS NO.1025967-78-5
|
CAS 1025967-78-5
|
1025967-78-5
|
Lifitegrast API
Difelikefalin
4-Piperidinecarboxylic Acid
|
1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)-4-aminopiperidine-4-carboxylic Acid
|
CAS#1024828-77-0
|
CAS NO.1024828-77-0
|
CAS 1024828-77-0
|
1024828-77-0
Gemcitabine HCl
Anti-tumor Gemcitabine
|
4-amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1h-pyrimidin-2-one Hydrochloride
|
CAS#122111-03-9
|
CAS NO.122111-03-9
|
CAS 122111-03-9
|
122111-03-9
|
Gemcitabine Hydrochloride API
|
Gemcitabine HCl API
|
Gemcitabine Hydrochloride
Pharmaceutical Intermediate
Gemcitabine HCl T9
CAS#134790-39-9
|
CAS NO.134790-39-9
|
CAS 134790-39-9
|
134790-39-9
|
Gemcitabine T9
Gemcitabine HCl T8
CAS#122111-11-9
|
CAS NO.122111-11-9
|
CAS 122111-11-9
|
122111-11-9
|
Gemcitabine T8
Gemcitabine HCl T6
CAS#122111-01-7
|
CAS NO.122111-01-7
|
CAS 122111-01-7
|
122111-01-7
|
Gemcitabine T6
Gemcitabine HCl T3
CAS#95058-92-7
|
CAS NO.95058-92-7
|
CAS 95058-92-7
|
95058-92-7
|
Gemcitabine T3
Tetrazole
1H-tetrazole
CAS NO.288-94-8
|
CAS 288-94-8
|
CAS#288-94-8
|
288-94-8
5-amino Tetrazole
CAS NO.4418-61-5
|
CAS 4418-61-5
|
CAS#4418-61-5
|
4418-61-5
Iminazole
4,5-Dicyanoimidazole
CAS NO.1122-28-7
|
CAS 1122-28-7
|
CAS#1122-28-7
|
1122-28-7
|
Imidazole-4,5-dicarbonitrile
|
4,5-Dicyanoimidazole DCI
Pyridine
2,6-Diaminopyridine
CAS NO.141-86-6
|
CAS 141-86-6
|
CAS#141-86-6
|
141-86-6
Heterocyclics
4-Nitrobenzoic Acid
CAS NO.62-23-7
|
CAS 62-23-7
|
CAS#62-23-7
|
62-23-7
News
Blog
Is 5-amino Tetrazole
|
What are the properties of 1H-tetrazole?
|
What are the side effects of using 2,6-Diaminopyridine?
|
What is the cost of Gemcitabine HCl T3 and is it covered by insurance?
|
Are there any clinical trials available for Gemcitabine HCl T6?
|
How is Gemcitabine HCl T8 administered to patients?
|
Are there any alternative treatments to Gemcitabine HCl T9 for cancer patients?
|
What are the uses of 4,5-Dicyanoimidazole?
|
What is 4-Nitrobenzoic Acid and Its Uses?
|
What is Urapidil Hydrochloride
|
How does Dexmedetomidine Hydrochloride affect the cardiovascular system?
|
What are the side effects of Rocuronium Bromide?
|
What are the side effects
|
What is the recommended dosage
|
What are the best ways to incorporate Garlicin
Company News
2023CPHI Barcelona
|
Gather together for a new chapter
|
Gather strength forge ahead|Jiangsu Runan Pharmaceutical Co.,LTD annual meeting &commendation meeting
|
2024CPHI Japan
|
Special practical drill for gas leakage accidents in the logistics department of the company in 2024
|
2023API Exhibition
|
Speech at the Advanced Experience Exchange Conference of Jiangsu Runan Pharmaceutical on Enterprise Safety Production in Industrial Parks
|
Comprehensive practical training for production safety accidents in 2023
|
Notice of Approval for Clinical Trials of Class 1 Innovative Drugs by Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd
|
Jiangsu Run'an Pharmaceutical Co., Ltd. Safety Production Month Activity Summary, Evaluation, Reward and Commendation Notice
|
Jiangsu Runan Pharmaceutical welcomes GMP inspection
|
Strengthen intellectual property protection and create an innovative highland
|
Chen Zhichang, Secretary of the Municipal Party Committee, conducted research on the construction of the new factory area of Zhengda Qingjiang Pharmaceutical
|
Announcement of Jiangsu Run'an Pharmaceutical Co., Ltd. before the 2023 Clean Production Audit
|
Sodium nitroprusside and urapidil, both antihypertensive drugs, have different contraindications and adverse reactions!
|
Pharmacological characteristics of dexmedetomidine and its application in postoperative delirium in elderly patients
|
Who is more effective, Elamod or Methotrexate
|
2024 CPHI CHINA Shanghai
|
2024 API Xi'an
Industry News
Lifitegrast
|
Difelikefalin-The first FDA-approved drug for the treatment of chronic kidney disease (CKD)-related pruritus-Difelikefalin injection
|
The advantages of Tetrazole
R&D
Send Inquiry
Contact Us
Wangjing
Hit enter to search or ESC to close
TOP
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies.
Privacy Policy
Reject
Accept